Search

Displaying results 5141 - 5150 of 6949 in total
  1. Drug

    AZD-4017

    go.drugbank.com/drugs/DB14875
    Investigational

    AZD-4017 is under investigation in clinical trial NCT01173471 (A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure).

  2. Drug

    NOP-1A

    go.drugbank.com/drugs/DB15208
    Investigational

    NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).

  3. Drug

    GLPG-1205

    go.drugbank.com/drugs/DB15346
    Investigational

    GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).

  4. Drug

    AEM-28

    go.drugbank.com/drugs/DB17642
    Investigational

    AEM-28 is a 28 amino acid mimetic of apolipoprotein E being investigated for lipid disorders, such as homozygous familial hypercholesterolemia. It possesses anti-inflammatory properties.[A258764]

  5. Drug

    Reloxiliase

    go.drugbank.com/drugs/DB17653
    Experimental

    It is being investigated for the treatment of hyperoxaluria.[A258823]

  6. Drug

    AGA2115

    go.drugbank.com/drugs/DB17840
    Investigational

    Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.[L46646]

  7. Drug

    IMMU-114

    go.drugbank.com/drugs/DB18458
    Investigational

    IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.

  8. Drug

    ALT-P1

    go.drugbank.com/drugs/DB18485
    Investigational

    It is under investigation for the treatment of growth hormone deficiency.

  9. Drug

    Timbetasin

    go.drugbank.com/drugs/DB19119
    Investigational

    Timbetasin is under investigation in clinical trial NCT05555589 (Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2).

  10. Drug

    RD13-02

    go.drugbank.com/drugs/DB27110
    Investigational

    RD13-02 is under investigation in clinical trial NCT05923541 (RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies).